{
    "root": "936ca777-7c42-4d88-a084-002df2b95f1c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "BOSULIF",
    "value": "20241219",
    "ingredients": [
        {
            "name": "BOSUTINIB MONOHYDRATE",
            "code": "844ZJE6I55"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE K25",
            "code": "K0KQV10C35"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "POLOXAMER 188",
            "code": "LQA7B6G8JG"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "bosulif indicated treatment : \u2022adult pediatric patients 1 year age older chronic phase ( cp ) philadelphia chromosome-positive chronic myelogenous leukemia ( ph+ cml ) , newly-diagnosed resistant intolerant prior therapy [ ( 14.1 , 14.2 , 14.3 ) ] . \u2022adult patients accelerated phase ( ap ) , blast phase ( bp ) ph+ cml resistance intolerance prior therapy [ ( 14.2 ) ] .",
    "contraindications": "\u2022 adult patients newly-diagnosed chronic phase ph+ cml : 400 mg orally daily food . ( 2.1 ) \u2022 adult patients chronic , accelerated , blast phase ph+ cml resistance intolerance prior therapy : 500 mg orally daily food . ( 2.1 ) \u2022 pediatric patients newly-diagnosed chronic phase ph+ cml : 300 mg/m 2 orally daily food . ( 2.1 ) \u2022 pediatric patients chronic phase ph+ cml resistance intolerance prior therapy : 400 mg/m 2 orally daily food . ( 2.1 ) \u2022 consider dose escalation increments 100 mg daily maximum 600 mg daily adult patients reach complete hematologic , cytogenetic , molecular response grade 3 greater . ( 2.2 ) \u2022 consider dose escalation increments 50 mg bsa < 1.1 2 100 mg bsa \u22651.1 2 maximum 600 mg daily pediatric patients reach sufficient response 3 months . ( 2.2 ) \u2022 adjust toxicity organ impairment ( 2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "bosulif contraindicated patients history hypersensitivity bosulif . included anaphylaxis [ ( 6.1 ) ] .",
    "indications_original": "BOSULIF is indicated for the treatment of:\n                  \n                     \n                        \u2022Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies (14.1, 14.2, 14.3)].\n                     \n                        \u2022Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2)].",
    "contraindications_original": "\u2022 Adult patients with newly-diagnosed chronic phase Ph+ CML: 400 mg orally once daily with food. ( 2.1 ) \u2022 Adult patients with chronic, accelerated, or blast phase Ph+ CML with resistance or intolerance to prior therapy: 500\u00a0mg orally once daily with food. ( 2.1 ) \u2022 Pediatric patients with newly-diagnosed chronic phase Ph+ CML: 300\u00a0mg/m 2 orally once daily with food. ( 2.1 ) \u2022 Pediatric patients with chronic phase Ph+ CML with resistance or intolerance to prior therapy: 400 mg/m 2 orally once daily with food. ( 2.1 ) \u2022 Consider dose escalation by increments of 100 mg once daily to a maximum of 600\u00a0mg daily in adult patients who do not reach complete hematologic, cytogenetic, or molecular response and do not have Grade 3 or greater adverse reactions. ( 2.2 ) \u2022 Consider dose escalation by increments of 50 mg for those with a BSA <1.1 m 2 and 100 mg for those with a BSA \u22651.1 m 2 to a maximum of 600 mg daily in pediatric patients who do not reach sufficient response after 3 months. ( 2.2 ) \u2022 Adjust dosage for toxicity and organ impairment ( 2 )",
    "adverseReactions_original": "BOSULIF is contraindicated in patients with a history of hypersensitivity to BOSULIF. Reactions have included anaphylaxis [see Adverse Reactions (6.1)]."
}